CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)\] in the treatment of acute myeloid leukemia (AML) that has not responded well to standard therapy or has returned after an initial remission (relapsed). The trial will be conducted at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC). Potential participants will go through a screening period to see if they are eligible to join the study. If eligible, participants will be hospitalized for 4-5 weeks to receive study treatment with CLAG-GO, called induction chemotherapy. If tests show that the cancer is in remission after induction chemotherapy, participants may undergo further chemotherapy (known as consolidation) or may proceed with bone marrow/stem cell transplantation. Patients who receive consolidation chemotherapy and remain in remission may have up to 8 cycles of outpatient maintenance therapy. A cycle lasts about 28 days. All participants will be monitored carefully for both side effects and to see if the study treatment is working. Lab tests and exams will be conducted throughout the entire study. In addition, special studies will be done at various time points to try to understand better how the drugs work and which patients are likely to respond best.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby dorosłe (powyżej 18 lat) z potwierdzoną diagnozą ostrej białaczki szpikowej (AML), z wyjątkiem ostrej białaczki promyelocytowej.
- •Pacjenci, u których choroba nawróciła lub nie zareagowała na co najmniej jedną serię intensywnego leczenia chemioterapią.
- •Pacjenci w dobrym ogólnym stanie zdrowia (zdolność do samodzielnego funkcjonowania).
- •Pacjenci, u których można wykazać obecność markera CD33 na komórkach białaczkowych.
- •Pacjenci z prawidłową pracą nerek i wątroby.
- •Pacjenci, którzy przeszli przeszczep komórek macierzystych, pod warunkiem spełnienia dodatkowych warunków dotyczących czasu od przeszczepu i braku choroby przeszczep przeciwko gospodarzowi.
✗ Disqualifies
- •Pacjenci z ostrą białaczką promyelocytową (APL).
- •Pacjenci, którzy niedawno przeszli inne terapie (z pewnymi wyjątkami, np. w celu zmniejszenia liczby białych krwinek).
- •Kobiety w ciąży lub karmiące piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Maryland Greenebaumn Comprehensive Cancer Center
Baltimore, United States
Trial contact
Veronica Kflu
Oyinkansola Arasanmi
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.